Revelation Biosciences Files Definitive Proxy Materials

TL;DR

REVB proxy filing is in, shareholders need to pay attention to upcoming votes.

AI Summary

Revelation Biosciences, Inc. filed a DEFA14A on January 13, 2025, related to its proxy statement. The company, formerly known as Petra Acquisition Inc. until April 23, 2020, is headquartered in San Diego, California, and operates in the pharmaceutical preparations sector. This filing is a definitive additional material.

Why It Matters

This filing provides shareholders with important information regarding upcoming corporate decisions and voting matters, impacting their investment in Revelation Biosciences.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement update and does not inherently introduce new financial or operational risks.

Key Players & Entities

• REVELATION BIOSCIENCES, INC. (company) — Registrant
• Petra Acquisition Inc. (company) — Former company name
• 20250113 (date) — Filing date
• 20200423 (date) — Date of name change
• SAN DIEGO, CA (location) — Company headquarters

FAQ

Key Financial Figures

• $200,000 — e for Proposal 2 saves the Company over $200,000 per year – San Diego, CA &#x20
• $200,000.00 — o Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All pro

Filing Documents

• revb_form_defa14a_2025-0.htm (DEFA14A) — 37KB
• img157140444_0.jpg (GRAPHIC) — 18KB
• 0000950170-25-004619.txt ( ) — 63KB

Forward-Looking Statements

Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words anticipate, believe, expect, estimate, plan, outlook, and project and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive

View Full Filing

View this DEFA14A filing on SEC EDGAR